Arrowhead Pharmaceuticals (NASDAQ: ARWR) Discloses on Its August 4 Fiscal Q2 2026 Conference Call the Full Terms of the Priority Review Voucher (PRV) Acquisition: $215 Million Paid to an Undisclosed Seller Under an Asset Purchase Agreement Expected to Close in Fiscal Q4 2026, Applied to the Plozasiran (Redemplo, ApoC-III-Targeting siRNA) Supplemental New Drug Application (sNDA) for Severe Hypertriglyceridemia (sHTG) Planned Before End of 2026 Following the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 Positive Readouts (79-81% Median Triglyceride Reduction, Significant Pancreatitis-Event Reduction); Arrowhead Projects a 3x Return on the $215 Million PRV Investment by Shifting the Plozasiran sHTG Uptake Curve Forward by Approximately Four Months (FDA Review Timeline Compressed From Standard 10 Months to 6 Months)
Arrowhead Pharmaceuticals (NASDAQ: ARWR) disclosed the full terms of its Priority Review Voucher (PRV) acquisition first mentioned on the August 4, 2026 fiscal Q2 2026 conference call. Terms: $215 million paid to an undisclosed seller under an asset purchase agreement expected to close in fiscal Q4 2026. Applied to: the plozasiran (Redemplo) supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG), planned for submission before end of 2026 following the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 positive readouts (79% SHASTA-3 and 81% SHASTA-4 median triglyceride reductions at Month 12 versus approximately 27% for placebo, plus statistically significant reductions in acute pancreatitis events). Return projection: Arrowhead management projects a 3x return on the $215 million PRV investment by shifting the plozasiran sHTG commercial uptake curve forward by approximately four months (the PRV compresses FDA new drug application review from the standard 10-month timeline to a 6-month priority review timeline). PRVs are transferable FDA-issued regulatory instruments awarded to sponsors that develop drugs for rare pediatric diseases, tropical diseases, or specific medical countermeasures; recent secondary-market transactions have priced PRVs in the $100-250 million range depending on demand and pipeline urgency. Redemplo (plozasiran) was FDA-approved November 2025 for familial chylomicronemia syndrome; the sHTG indication would substantially expand the addressable patient population.